CSSi News

DIA 2018 - See you next week?

June 19, 2018

MyClinicalTrial ID

Accelerating Patient Recruitment

 

CSSi works quickly, before the popsicle melts

Take a bite out of our
HIGH-IMPACT
STUDY ENROLLMENT
SUPPORT

Time is
melting
away!

Ask us how we can
help get your study
back on track!
 

Join us at #DIA2018 from June 25-27! Stop by our Booth #2305 and submit your business card for three chances to win a Kate Spade tote.

If you're interested in scheduling a one-on-one meeting with a CSSi representative during DIA, go to www.cssienroll.com/event.html.

We look forward to seeing you in Boston!

 
 

CSSi to Showcase Latest Innovations at 53rd Drug Information Association Annual Meeting

June 5, 2017

Unique Patient Recruitment Solutions to Help Solve the Industry's Biggest Challenges


Glen Burnie, MD – CSSi, the global leader in patient recruitment, enrollment, and retention solutions for the clinical research industry, will be exhibiting in booth #1951 at the upcoming 53rd Drug Information Association (DIA) Annual Meeting. During the event, CSSi will present demonstrations of its newest innovative technology offerings, MyClinicalTrial ID and CSSi Connect, to DIA 2017 attendees. The demonstrations will illustrate how these tools will transform the way sites and patients are selected, trials are enrolled, and patients are engaged.

"CSSi is thrilled to be a part of the DIA 2017 exhibitor lineup and have the opportunity to share our game-changing technologies with some of the industry's most notable thought leaders and potential customers," says Chris Trizna, President, CSSi. "For over 12 years, CSSi has been providing global patient recruitment and retention services directly to sites, CROs, and Sponsors. Our involvement with this event will allow us to continue our mission to exceed our customers' expectations by offering innovative solutions and outstanding services to enroll studies faster, in order to successfully get drugs and devices to patients in need."

MyClinicalTrial ID and CSSi Connect were developed with help from CSSi's in-house technology division, Nexus Informatics, to lessen the impact of recruitment and retention challenges within the rapidly-evolving industry. Making its debut at DIA 2017, MyClinicalTrial ID will help identify qualified sites for a study based on a validated patient population data against protocol I/E criteria. CSSi's patient engagement portal, CSSi Connect, was launched at DIA 2016 to help maintain patients' interest and enhance site-patient communication during a study. Both technologies will work hand-in-hand to positively impact the feasibility, patient recruitment, and retention of a study.

DIA 2017 is the largest, longest-running global interdisciplinary drug industry event that encourages innovation and supports the advancement of safe and effective medical products and therapies to patients. This year's event will bring together more than 7,000 life sciences professionals and feature more than 450 exhibiting companies, 11 tracks, 15 hot topics, and 160 sessions. The five-day event is scheduled to take place at the McCormick Place in Chicago, Illinois from June 18-22, 2017.

To arrange an in-person meeting with CSSi's patient recruitment experts at DIA 2017, please fill out the form at www.CSSiEnroll.com/event.htm or email: marketing@CSSiEnroll.com.

About CSSi:

CSSi delivers global patient recruitment solutions to study sponsors, CROs, SMOs, and investigative sites that ensure successful enrollment on time, every time. Through its innovative enrollment planning and full-service patient recruitment solutions, CSSi is able to reduce the costs and timelines associated with recruitment of subjects for clinical studies. For more information on CSSi, please email: info@CSSiEnroll.com or call: (866) 277-4888.

Follow Us!
Facebook.com/CSSiEnrollTwitter.com/EnrollPatientsLinkedIn.com/Company/Clinical-Site-Services

Media Contact:
Courtney Megaughey
CSSi
(443) 308-5831
cmegaughey@CSSiEnroll.com


Global Patient Recruitment Company CSSi Launches Redesigned Website

May 10, 2017

MyClinicalTrial ID

The new website offers improved functionality and increased benefits to visitors

CSSi, the global leader in patient recruitment, enrollment and retention solutions for the clinical research industry, is proud to announce the launch of its newly redesigned website, www.CSSiEnroll.com. The new website features both enriched content and a customized layout that provides a better overall user experience and enhances the company's already well-established position as the top global patient recruitment company in the industry.

"After many months of hard work, we are delighted to officially announce the relaunch of our new and improved company website," said Chris Trizna, President, CSSi. "We hope our redesigned website exceeds our current and prospective clients' expectations; we really worked hard to make sure it contains valuable patient recruitment information, solutions and services to assist them with meeting their enrollment goals. With the changes and upgrades, we expect maximized audience engagement and tremendous leads through our new convenient, user-friendly website."

The goal of CSSi's website redevelopment effort was focused on aesthetics, simplifying content and increasing the visibility of the company's brand. The new website is both visually appealing and user-friendly which provides visitors with streamlined menus, clear navigation and better access to useful information about the company's outstanding services and recent successes.

Newly revamped pages of www.CSSiEnroll.com include:

  • Capabilities – Navigate through a library of tools and service offerings, customizable to each study, that CSSi utilizes to ensure the most efficient and cost-effective method to reaching a client's enrollment goals.
  • Therapeutic Areas & Case Studies – Highlights CSSi's vast patient recruitment experience, with the completion of over 1,200 studies in the last three years within 17 therapeutic areas and 120 unique indications.
  • CSSi Creative Profile – Showcases the company's broad scope of work and various creatives that have been used to successfully recruit patients. Users can get an in-depth look into CSSi's creative development process, which involves a thorough analysis of the industry, health indication and a client's needs and challenges. CSSi strives to develop a unique, powerful study brand and the enrollment tools that each investigative site needs to effectively enroll study subjects.

The website relaunch comes on the heels of CSSi's 12-year anniversary. "I am so incredibly proud of my team and all that we have accomplished over the years and to be a part of an industry that brings new drugs and devices to market to help people with chronic illnesses all across the globe. Our quality of work has been top notch and crucial to our continued patient recruitment success. We look forward to many more years of growth for CSSi and the industry!" added Trizna.

About CSSi:

CSSi delivers global patient recruitment solutions to study sponsors, CROs, SMOs and investigative sites that ensure successful enrollment on time, every time. Through its innovative enrollment planning and full-service patient recruitment solutions, CSSi is able to reduce the costs and timelines associated with recruitment of subjects for clinical studies. For more information on CSSi, please email: info@CSSiEnroll.com or call: (866) 277-4888.

Follow Us!
Facebook.com/CSSiEnrollTwitter.com/EnrollPatientsLinkedIn.com/Company/Clinical-Site-Services

 

Media Contact:
Courtney Megaughey
Public Relations and Marketing Coordinator
CSSi LifeSciences
(443) 308-5831
Cmegaughey@cssienroll.com

 

Introducing

November 2, 2016

MyClinicalTrial ID

CSSi's MyClinicalTrial ID is unique in that it can be used during site feasibility and patient recruitment, from a secure and compliant virtual, cloud-based system.

MyClinicalTrial ID Features & Benefits Include:

Site Feasibility - Accurately identifies the most productive sites by providing a snapshot of the site's true patient population for eligibility. Site selection is based on EMR patient-centric data.

Patient Recruitment - Rapidly and efficiently identifies the most eligible patients by providing sites an automated protocol query against their database, presenting only those patients who meet the protocol's entry criteria. When paired with our Local Enrollment Specialist solution, this platform makes it easy for busy sites to accurately identify and recruit eligible patients.

CSSi Exhibiting at the 52nd Drug Information Association Annual Meeting in Philadelphia, PA

June 1, 2016

CSSi MD Food Bank

Glen Burnie, MD – CSSi, the global leader in patient recruitment, enrollment and retention solutions for the clinical research industry, today announced that the company will be exhibiting in booth 1000 at this year's 52nd Drug Information Association (DIA) Annual Meeting. The five-day event is scheduled to take place from Sunday, June 26 – Thursday, June 30, 2016 at the Philadelphia Convention Center in Philadelphia, PA.

DIA 2016 is the largest global interdisciplinary drug industry event bringing together an extensive network of life science professionals at all levels and across all disciplines to encourage innovation and support the development of safe and effective medical products and therapies to patients. With over 7,000 conference attendees expected, CSSi will have the rare opportunity to increase its knowledge of the development of new therapies and quicken efforts to enhance health and well-being globally, as well as facilitate trusted relationships with the top industry leaders and established organizations that drive and share a similar mission and values. It will provide CSSi with an invaluable learning experience and a chance to showcase its global therapeutic experiences, patient engagement capabilities, and unique Local Enrollment Specialist services.

"CSSi is excited to participate in this year's 'can't miss event' as an exhibitor," says Chris Trizna, President, CSSi. "At DIA 2016, we look forward to further expanding our industry reach and enabling more companies to not only meet, but also exceed, their patient recruitment and enrollment goals."

DIA 2016 will provide an instrumental opportunity for global innovators involved in the discovery and commercialization of pharmaceuticals, medical devices, and related products, including discussion of current and evolving areas such as comparative effectiveness research, health outcomes, and drug/device combination products. The event will feature over 95 senior leaders from international regulatory authorities, more than 75 educational offerings over 22 tracks on today's most relevant industry topics, and numerous panel discussions conducted by leaders from the International Coalition of Medicines Regulatory Authorities (ICMRA), among other organized activities.

CSSi is the only global patient recruitment organization that tailors its support and services around each individual site's needs to help it successfully reach patient recruitment goals. With decades of experience and thousands of trials supported globally and nationally, CSSi is a full-service company with an array of superb patient recruitment, enrollment, and retention solutions.

About CSSi:

CSSi delivers global patient recruitment solutions that ensure successful enrollment, on time, every time. Through its innovative enrollment planning and full-service patient recruitment solutions, CSSi is able to reduce the costs and timelines associated with recruitment of subjects for clinical studies. For more information on CSSi, visit www.CSSiEnroll.com, or email at info@cssienroll.com.

 

Media Contact:
Courtney Megaughey
Public Relations and Marketing Coordinator
CSSi LifeSciences
(443) 308-5831
Cmegaughey@cssienroll.com

 

CSSi LifeSciences™ Hosting During the J.P. Morgan 34th Annual Healthcare Conference

Post date: December 9, 2015

CSSi J.P. Morgan

CSSi LifeSciences™ along with their strategic partners, PRC Clinical and Statistics & Data Corporation will have a Hospitality Suite during the upcoming J.P. Morgan Annual Healthcare Conference, to be held in San Francisco, January 11 – January 14, 2016.

The annual event provides an opportunity for life science, biotech and health companies to meet with potential investors with billions of dollars under management, pensions, foundations and endowments.

Located at the Hilton San Francisco Union Square, CSSi LifeSciences™ and their strategic partners will be hosting in the Golden Gate 1 meeting room for each of the four days beginning at 8 am. A featured guest speaker will be presenting each day on specific topics of interest. The presentation schedule will be posted at a later date at www.CSSiLifesciences.com

About CSSi LifeSciences™

CSSi LifeSciences™ provides fully integrated, specialized regulatory and clinical services to support the entire product lifecycle, from discovery to commercialization, for pharmaceutical and medical device companies. With global expertise, CSSi LifeSciences™ has been a key partner in the development of more than 500 drugs, biologics, medical devices and in-vitro diagnostics.

About PRC Clinical

PRC Clinical is a Silicon Valley-based CRO specializing in Clinical Trial Management, supporting phase I-IV clinical studies for pharmaceutical and medical device companies globally in 19 countries. Visit www.prcclinical.com.

About Statistics & Data Corporation

Statistics & Data Corporation (SDC), based in Tempe, Arizona, is a specialized data services Contract Research Organization (CRO) providing scalable full-service solutions since 2005. For more information, visit www.sdcclinical.com.

 

Media Contact:
Courtney Megaughey
Public Relations and Marketing Coordinator
CSSi LifeSciences
(443) 308-5831
Cmegaughey@cssienroll.com

 

CSSi Lifesciences™ Partners with AccenGen to Develop New Class of Anti-inflammatory Drugs

Post date: December 8, 2015

New anti-inflammatory drug

Glen Burnie, MD - CSSi LifeSciences™ (www.CSSiLifeSciences.com) has formalized an agreement with AccenGen, a San Francisco based early-stage pharmaceutical company to develop novel drugs that hold great promise in the treatment of a range of inflammation-related conditions.

AccenGen selected CSSi LifeSciences™ because of its best in class services to efficiently develop AccenGen's soluble epoxide hydrolase (sEH) inhibitors and ensure the most efficient path to drug development. sEH inhibitors are a new class of anti-inflammatory drugs that target problems at the source, providing a safer, more effective mechanism of treatment for patients. sEH inhibitors have been indicated as a treatment for a range of diseases and conditions including scleroderma, fibrosis, asthma, atrial fibrillation, arrhythmias, sinusitis, allergies and pain.

"We are excited to establish our strategic partnership with AccenGen to leverage our strategic commercial drug development services to develop a novel new class of drugs. The sEH inhibitors have the potential to address a large unmet need," said Jim Sergi, President of CSSI LifeSciences™.

About CSSi LifeSciences™

CSSi LifeSciences™ provides fully integrated, specialized regulatory and clinical services to support the entire product lifecycle, from discovery to commercialization, for pharmaceutical and medical device companies. As a trusted partner, CSSi LifeSciences™ provides a comprehensive suite of scalable services with cost efficient predictability, which drives product value, extends market share, and maximizes ROI. With global expertise, CSSi LifeSciences™ has been a key partner in the development of more than 500 drugs, biologics, medical devices and in-vitro diagnostics. Visit www.CSSiLifeSciences.com or contact Jim Sergi at jsergi@cssienroll.com

About AccenGen

AccenGen Therapeutics, Inc. is an early stage pharmaceutical company focused on developing products using soluble epoxide hydrolase (sEH) inhibitors and (sEHI) for indications with inflammatory etiologies, highest unmet needs and largest markets. For more information, visit www.accengen.com, call (844) 422-2364, or email: info@AccenGen.com

 

Media Contact:
Courtney Megaughey
Public Relations and Marketing Coordinator
CSSi LifeSciences
(443) 308-5831
Cmegaughey@cssienroll.com

 

CSSi LifeSciences™ and PRC Clinical Join Forces to Offer Extended Clinical Trial Services

Post date: July 29, 2015

CSSi Team Work

Glen Burnie, MD - CSSi LifeSciences™ (www.CSSiLifeSciences.com) formalized a strategic partnership agreement with PRC Clinical, a Silicon Valley-based CRO specializing in Clinical Trial Management. CSSi LifeSciences™ is specialized in strategic, marketing, and regulatory consulting, FDA advisory services, and patient recruitment services. The core expertise of PRC Clinical is focused on Clinical Trial Management, Clinical Site Monitoring, and Clinical Payment Services. The CSSi LifeSciences™ and PRC Clinical partnership equips both firms with the ability to guide and support sponsors through the entire drug development lifecycle, from strategic, regulatory, clinical operations, and marketing standpoints.

CSSi LifeSciences™ has successfully supported the development of over 500 new drugs, biologics, medical devices and in-vitro diagnostics for sponsors in the United States, Europe, Asia, and the Middle East. PRC Clinical has supported phase I-IV clinical studies for pharmaceutical and medical device companies globally. CSSi LifeSciences™ and PRC Clinical are respectively headquartered in Baltimore, MD and San Bruno, CA. The signature of this partnership agreement will strengthen both firms in their ability to seamlessly support sponsors across the United States and Globally.

"We are excited to establish our strategic partnership with PRC Clinical to leverage our skills, services and brain trust to help bring complementary and specialized clinical trial services to local and global clients," said Jim Sergi, President of CSSI LifeSciences™. The new partnership benefits pharmaceutical and medical device companies by simplifying the outsourcing process for full-service projects.

"The PRC Clinical team is excited to work in a formalized relationship with CSSi LifeSciences™ and to support local and global clinical trials across the drug development lifecycle," stated Curtis Head, CEO at PRC Clinical.

CSSi LifeSciences™ and PRC Clinical share a strong belief in providing personalized client and patient centric services, as well as a similar management style in providing uncompromising SOP driven standards. In joining resources, clients will receive best in class services to provide insight driven analysis and more informed decision making to increase commercial success, while reducing the risk for late-stage failures and post-authorization action.

About CSSi LifeSciences™

CSSi LifeSciences™ provides fully integrated, specialized regulatory and clinical services to support the entire product lifecycle, from discovery to commercialization, for pharmaceutical and medical device companies. As a trusted partner, CSSi LifeSciences™ provides a comprehensive suite of scalable services with cost efficient predictability, which drives product value, extends market share, and maximizes ROI. With global expertise, CSSi LifeSciences™ has been a key partner in the development of more than 500 drugs, biologics, medical devices and in-vitro diagnostics. Visit www.CSSiLifeSciences.com or contact Jim Sergi at jsergi@cssienroll.com

About PRC Clinical

PRC Clinical is a Silicon Valley-based CRO specializing in Clinical Trial Management, supporting phase I-IV clinical studies for pharmaceutical and medical device companies globally in 19 countries. Founded in 2003, PRC Clinical offers Clinical Trial Management services including Site Monitoring, Quality Assurance, Drug Safety, Clinical Project Management, Payment Services, Biostatistics, Data Management, and CTMS. PRC clinical has significant CRO experience in conducting phase I-IV clinical studies in a wide range of Therapeutic areas & Case Studies: CNS, Neurology, Pain, GI, Device, Anti-infective, Cardiovascular, Pulmonary, Oncology, Endocrine, ALS, Parkinson's, and Stem cells. Visit http://www.prcclinical.com, call 1-877-519-6001, or email info@prcclinical.com .

 

Media Contact:
Courtney Megaughey
Public Relations and Marketing Coordinator
CSSi LifeSciences
(443) 308-5831
Cmegaughey@cssienroll.com

 

CSSi in the Community

November 2017

Alzheimer's Awareness

Did you know that NOVEMBER is National Alzheimer's Disease Awareness and Caregivers Month?

Alzheimer's disease is the sixth leading cause of death in the U.S. An estimated 5.3 million Americans age 65 and older have Alzheimer's disease, and nearly 14 million Americans may suffer from it by 2050.

CSSi is committed to finding a solution for this unmet medical need:

  • CSSi has supported 500+ recruitment campaigns around the world
  • CSSi has worked with 200+ sites developing and implementing successful enrollment plans
  • CSSi has worked with hundreds of advocacy and caregiver organizations associated with Alzheimer's patients to raise awareness about the condition and clinical trial
  • CSSi has participated in many local awareness walks in the past 10 years raising thousands of dollars and walking 100+ miles
  • CSSi's Deborah Hanna - an Alzheimer's Association facilitator, experienced geriatric care manager and the founder of PALS, a monthly social group for women who are caregiving for husbands/partners with dementia
CSSi participating in Alzheimer's Disease Awareness

CSSi's Unique Services for Alzheimer's Disease

We have developed custom services that are unique to Alzheimer's disease and other CNS studies to increase the recruitment and retention of patients in studies. These services include:

MyClinicalTrial ID logo

MyClinicalTrial ID - Decreases a study's feasibility, site selection and patient recruitment timeline by identifying sites with eligible patients comparing de-identified, real-time medical data versus protocol inclusion/exclusion criteria.

support people

Local Enrollment Specialists - Former study coordinators who fully understand the challenges sites face when enrolling research studies. Our LES team offers customizable enrollment plans for each site, clinical trial and study team to exceed sponsor enrollment goals and timelines.

people in a circle

Local Enrollment Specialists - Former study coordinators who fully understand the challenges sites face when enrolling research studies. Our LES team offers customizable enrollment plans for each site, clinical trial and study team to exceed sponsor enrollment goals and timelines.

computer

Media Planning and Placement - CNS recruitment campaigns must be well thought out and strategically planned to maximize recruitment results. The CSSi media team has placed over $5,000,000 on Alzheimer's, Depression, and other CNS studies.

Have an Alzheimer's disease clinical trial we can support?

Come Meet Us at CNS Summit 2017!

From November 16-19, CSSi President Chris Trizna will be attending the conference in Boca Raton, FL, where he will discuss our unique solutions that have increased enrollment and retention rates for Alzheimer's disease and other CNS-related studies. To set up a face-to-face with Mr. Trizna, please fill out our meeting request form here: www.cssienroll.com/event.html.

October 2017

LGS Awareness Day Event

CSSi Attending LGS Event

Over the weekend, CSSi attended the Lennox-Gastaut Syndrome (LGS) Foundation's annual 'LGS Awareness Day Event' at the National Aquarium in Baltimore, MD. This year's theme was "Sea of Hope". Individuals living with LGS and their families gathered from all over to country to spend a fun-filled evening with some of the world's aquatic treasures. The sold-out event was a great success, and it served its purpose of helping to raise funds to improve the lives of individuals with LGS. It was a great night, for a great cause!

To learn more about the LGS Foundation and its mission, visit: www.lgsfoundation.org.


October 2017

Breast Cancer Awareness

CSSi wearing pink

Are you tough enough to wear pink? October is Breast Cancer Awareness Month. CSSi understands the importance of bringing awareness to breast cancer and other cancers through clinical trial awareness and education as well as workplace activities.

This year, CSSi encouraged its employees to wear their best pink attire for "Wear Pink" Wednesdays during the month of October, to help raise awareness and show its support for the 1 in 8 women who struggle with breast cancer. We also donated to the National Breast Cancer Foundation . CSSi was the cause of a significant donation towards a cure for breast cancer. National Breast Cancer Foundation. CSSi was the cause of a significant donation towards a cure for breast cancer.


September 2017

MD Food Bank

CSSi Giving Back at the Maryland Food Bank

CSSi volunteers donated their time to the Maryland Food Bank to help end hunger in Maryland.


June 2017

CSSi table, Becky NAMI walk 2017

The lack of clinical trial awareness is an on-going challenge for patient recruitment. The goal of CSSi is to educate the public about the importance of clinical research by providing the adequate tools and resources needed to help individuals make informed decisions about participating in clinical trials that are available and right for them.

In support of a treatment-resistant depression study, CSSi participated in the National Alliance on Mental Illness (NAMI)'s NAMIWalks Oklahoma to increase awareness about clinical trials and encourage participation. NAMIWalks are held in various communities across the nation to raise awareness of mental illness and raise funds for local, regional and state NAMI organizations.

Through our continued community outreach efforts, we hope that the individuals we connect with will have a better understanding of clinical trials and a new appreciation for the industry.

April 2017

CSSi Company Golf Outing

In celebration of Clinical Trials Day, CSSi took a trip to the Arundel Golf Course, where we played miniature golf and hit the batting cages. It was an afternoon full of good company, yummy snacks and drinks, and multiple holes in one.

April 2017

CSSi Convoy of Hope

In early April, one of CSSi's Local Enrollment Specialists attended the Convoy of Hope San Antonio community event to raise awareness for a nationwide clinical trial we are supporting.

CSSi loves getting involved and connecting with not only the Baltimore community but communities across the country that are home to the research sites we provide our patient recruitment services to.

Our community outreach team and Local Enrollment Specialists do an incredible job of identifying opportunities to connect with patients and physicians in the community. We aim to make a difference, bring hope to those who need it the most and have a long-lasting positive impact on the health and medical communities.

December 2016

CSSi SPAN

CSSi assumed the role of Santa's helpers for the SPAN, Inc. 2016 Holiday Caring Program, where our staff shopped for, wrapped and placed Christmas gifts under the Christmas tree for the taking. Our contributions will go to a select few of the many local area families and children that SPAN is providing gifts to this year. Through our efforts, we hope we can spread some holiday cheer and help create new holiday memories for our neighbors in need!

November 2016

CSSi SPAN

CSSi staff, family, and friends showed their continued support for SPAN, Inc., it's mission, and local Anne Arundel County area families in crisis by participating in the 2016 Stride for SPAN 5K Race/1 Mile Fun Walk. The event was a great success and very rewarding for all of our participants! We are already looking forward to next year's event!

November 2016

CSSi ALZ Walk

November is National Alzheimer's Disease Awareness & Caregivers Month! CSSi is committed to supporting Alzheimer's research through community events, our in-office expert, existing networks, and the success of our services. We took the first step to a world without Alzheimer's by participating in not just one, but two, Walk to End Alzheimer's in the Greater Baltimore and Anne Arundel County areas. Get involved now and help raise awareness in your community! Join the movement to ending Alzheimer's disease by visiting the Alzheimer's Association's website - www.alz.org.

September 2016

CSSi VEDA

CSSi decided to join in on the fun and wanted show our support for Vestibular Disorders Association (VEDA) by participating in its "Flat Flamingo Photo Contest". This photo challenge is meant to help raise awareness about vesitbular disorders. We challenge you to flaunt your Flat Flamingo and help VEDA #defeatdizziness! Learn more about VEDA and how to get involved or donate: vestibular.org.#BalanceAwarenessWeek

August 2016

CSSi MD Food Bank

CSSi had two groups of eager volunteers pitch in at the Maryland Food Bank to help support the movement to end hunger in MD. The teams sorted and packed food delivered to its warehouse as well as helped bag and flash-freeze meals from its kitchen, all to be distributed to its network of partners. It was a very rewarding experience, and we look forward to continuing our long-standing commitment to volunteerism at our next community outing! Learn more about the Maryland Food Bank's hunger relief efforts and available volunteer opportunities here: http://bit.ly/2bYlxWA.

June 2016

CSSi Alzheimer's Awareness month

Our staff dressed down for the day and wore purple in support of Alzheimer's & Brain Awareness Month! We wanted to join in on the movement of helping shine a purple light for the millions of individuals around the world and all of the people in our community who are affected by Alzheimer's. We challenge you to do the same! #ENDALZ

April 2016

CSSi Serverna Park High School Run

This past Saturday, the CSSi team took part in the Run 4 Rhythm Fun Run/Walk at Severna Park High School (SPHS). With help from some formal training and the beautiful weather, CSSi participants were able to the complete the four-mile-long course, along the B&T Trail, with ease. Proceeds from this exciting event benefited the SPHS Band & Orchestra Boosters. Congratulations to all participants and on a successful event!

picture of Charlie Speno

Charlie Speno Returns to CSSi as Vice President of Business Development

August 30, 2017

Speno Brings Extensive Knowledge of Design and Deployment of Patient and Site Engagement Strategies to Baltimore-based Patient Recruitment Company


Glen Burnie, MD – CSSi, the global leader in patient recruitment, enrollment and retention solutions for the clinical research industry, is pleased to announce the return of Charlie Speno as Vice President of Business Development. In this role, Speno will lead CSSi's growing business development team in generating new sales opportunities and building long-term client relationships.

"Charlie brings a unique perspective to the clinical research industry and to CSSi's pharmaceutical and device clients," said Chris Trizna, President, CSSi. "His commitment to the excellence and innovation in patient recruitment is truly unmatched. He will be able to bring our latest EMR validation tool and patient engagement retention solution to a whole new level. As a respected business leader within the industry and a valuable asset to our team, we are delighted to welcome him back."

Since entering the pharmaceutical industry in 1997, Speno has had a passion and continued interest centering around the patient journey. Speno returns to CSSi with nearly two decades of clinical and sales management experience in the pharmaceutical, biotech and medical device industries. Prior to rejoining CSSi, Speno served for five years as the Vice President of Business Development, focusing on patient engagement, innovation and adherence, at United BioSource Corporation.

"I continue to be impressed by how much CSSi has accomplished over the past 12 years," said Speno. "CSSi is successful because it doesn't complicate the patient enrollment process, but rather simplifies it with the use of its comprehensive clinical trial support tools and services. I am humbled to be a part of such a hardworking team and can't wait to further contribute to CSSi's growth and success."

CSSi specializes in providing the latest-and-greatest patient recruitment technologies, traditional media and outreach services to sites. Speno and the CSSi team will be exhibiting in booth #606 at Global Sites Solutions Summit, scheduled to take place in Boca Raton, FL from October 6-8, 2017. To arrange an in-person meeting with CSSi's patient recruitment experts, please fill out the form at www.CSSiEnroll.com/event.html.

About CSSi:

CSSi delivers global patient recruitment solutions to sponsors, CROs, SMOs, and investigative sites that ensure successful enrollment for clinical trials - on time, every time. CSSi brings years of patient recruitment and retention knowledge across all disciplines: recruitment planning and budgeting, media advertising, website and creative development, project management, marketing and consulting, and technology solutions. CSSi is headquartered in Baltimore, MD. For more information, please visit: www.CSSiEnroll.com email: info@CSSiEnroll.com or call: (866) 277-4888.

Follow Us!
Facebook.com/CSSiEnrollTwitter.com/EnrollPatientsLinkedIn.com/Company/Clinical-Site-Services




Strategies for Studies that Don't Take a Vacation

Post date: July 17, 2017

CSSi Summer Recruitment 2017

Digital Advertising

Traditional advertising may push recruitment effort 80% of the way to its destination, but only with integrated digital efforts like Facebook and Google does the study get pushed to reaching its goals.


Radio Advertising

Advantages:

•     Longer daylight hours, youth and adult sports participation, and summer events all encourage more time driving and listening to the radio

•     Fringe hours like 7-8 p.m., or even 7-9 p.m., can be a very inexpensive way to increase message frequency and reach listeners during the early evening hours-normally not an ideal time slot during the winter months

Disadvantages:

•     Mondays and Fridays are more likely to be impacted by long holiday or summer vacation weekends

•     Radio demand and higher costs will occur ahead of July 4th, August back-to-school and Labor Day weekend, so plan accordingly


Television Advertising

Advantages:

•     Daytime TV viewing may be at lower audience levels, but it is still the best way to reach the broadest audience across an entire market area

•     Potential patients with health issues often use TV as a relaxing escape when confined at home

•     People watching the news - national, political, global, and weather events (e.g. summer hurricane season) - can elevate TV viewing

Disadvantages:

•     Many popular shows are in reruns, (e.g. Ellen, Dr. Phil)

•     With news programming having consistent viewing, rates will not be that much lower, so budget accordingly


Political Impacts

•     Some markets across the U.S. will see increased political spending due to off-year elections:

    o     N.J. Governor's race, Virginia Governor, Alabama Senate (special election), etc.

    o     Health coverage and other issue advertising

Let CSSi help you plan and place your media this summer!




Follow Us!
Facebook.com/CSSiEnrollTwitter.com/EnrollPatientsLinkedIn.com/Company/Clinical-Site-Services

Media Contact:
Courtney Megaughey
CSSi
(443) 308-5831
cmegaughey@CSSiEnroll.com


Focus on Rare Disease

Over 350 million people are affected by the lack of treatments available for 7,000 rare diseases. CSSi and its family of companies, CSSi LifeSciences and Nexus Informatics, work in unison to develop comprehensive solutions to regulatory, clinical, recruitment and technology challenges.
Supporting Research for Rare Diseases image

CSSi LifeSciences

CSSi LifeSciences has extensive experience to help navigate the proposed new FDA regulatory changes and clinical complexities of the US FDA and the EMA orphan drug designations to optimize clinical development plans and speed up evaluation so medicines can reach patients earlier, while driving shareholder value. Experience includes:

  • Over 14 rare therapeutic areas, including pediatrics, in 40 countries
  • Common EMA-FDA Harmonized Application for Orphan Medicinal Products
  • Proven success with the FDA Clinical Grants Program for Orphan Drug funding
  • EMA's PRIME program; to enhance support for the development of medicines that target an unmet medical need
  • EMA in-country representation and registration through our London office

CSSi Global Patient Recruitment

Nexus Informatics

Nexus Informatics' offers an end-to-end technology solution with up-front automation and back-end data analytics so that pharmaceutical manufacturers can gain enterprise-wide efficiencies. Nexus Informatics technology and portals currently supports:

  • Unique patient engagement and access programs
  • 1,400+ call center users
  • 2,200+ healthcare professionals (HCPs)
  • 1,100+ field based users

We have the experience, expertise and tools for all of your rare disease needs, from pre-clinical, clinical trials, and post-commercialization.

Rare Disease Experience

Acute Myeloid Leukemia
AML
Amyloidosis
Chronic Hepatitis B
CIS Bladder
Cystic Fibrosis
Glioblastoma
Grave's Disease
Guillain-Barre Syndrome

Hemophilia A
Hemophilia B
Idiopathic Pulmonary Fibrosis
Juvenile Rheumatoid Arthritis
Krabbe Disease
Meniere's Disease
Mesothelioma
MS
Multiple Myeloma

Muscular Dystrophy
NASH
Prader Willi Syndrome
Rubinstein-Taybi
Sickle Cell Disease
Stage IV Metastatic Breast Cancer
Systemic Scleroderma
Uveitis

 

About CSSi LifeSciences:
CSSi LifeSciences ensures a successful and expeditious pathway to commercialization for our clients' drugs and medical devices by providing insight-driven analysis that saves time, development costs and resources. CSSi LifeSciences enables faster, more informed decision making to increase commercial success, while reducing the risk of late-stage failures and post-authorization action. CSSi LifeSciences is headquartered in Baltimore, MD, with additional offices in San Francisco, CA, London, UK and Hyderabad, India. For more information, please visit: www.cssilifesciences.com, email: info@CSSiLifesciences.com or call: (888) 279-8388.

 

 

CSSi to Sponsor LGS Awareness Event

Dive In to a Sea of Hope recognizes individuals living with Lennox-Gastaut Syndrome

Glen Burnie, MD (October 13, 2017) – CSSi is proud to announce it will be a sponsor of the Dive In to a Sea of Hope fundraiser on Saturday, October 28, 2017, at the National Aquarium in Baltimore, MD. Produced by the LGS Foundation, a New York-based non-profit organization dedicated to providing information about Lennox-Gastaut Syndrome (LGS), the event is aimed at recognizing LGS and International LGS Awareness Day, which is celebrated annually on November 1.

It is estimated that less than 50,000 individuals in the United States live with LGS. LGS is a rare and often a debilitating form of epilepsy that involves frequent seizures and affects children and adults. There is currently no cure for this disorder.

"CSSi is honored to have the opportunity to support such a worthy cause and the LGS Foundation, which is committed to improving the lives of individuals with LGS through research, programs and education," said Chris Trizna, president, CSSi. "As an active member of the LGS community, CSSi works to develop and execute recruitment plans with multiple tactics designed to reach and educate individuals and families affected by the disease as well as create study awareness in sites' communities."


CSSi Attendees

Over the years, CSSi has provided support to hundreds of neurology and primary care sites so they are able to efficiently screen patients within the desired enrollment timeline. The patient recruitment company has completed over 150+ CNS/neurology programs, including over 20 focused on epilepsy in pediatric and adolescent patients. CSSi's innovative methods and technologies have also successfully enrolled and retained thousands of patients in many rare disease clinical trials, such as Meniere's disease, hemophilia A, amyloidosis, multiple myeloma, just to name a few.

The event will start at 6 p.m. and include a self-guided, one-hour tour, followed by a reception with hors d'oeuvres and cocktails. To learn more about the LGS Foundation and purchase tickets for the upcoming event, please visit: www.lgsfoundation.org.

CSSi Sponsors LGS Awareness Event

About CSSi:

CSSi delivers global patient recruitment solutions to sponsors, CROs, SMOs, and investigative sites that ensure successful enrollment for clinical trials - on time, every time. CSSi brings years of patient recruitment and retention knowledge across all disciplines: recruitment planning and budgeting, media advertising, website and creative development, project management, marketing and consulting, and technology solutions. CSSi is headquartered in Baltimore, MD. For more information, please visit: www.CSSiEnroll.com, email: info@CSSiEnroll.com or call: (866) 277-4888.

 

Enhance Cancer Clinical Trial Awareness, Increase Enrollment

October 26, 2017

Approximately 1.7 million people are diagnosed with cancer in the United States each year, but only 3% are enrolled in clinical trials

This is a very unsettling statistic – and there are many factors that contribute to it: lack of clinical trial education and awareness, fear of reduced quality of life, concern about receiving placebo, potential side effects, and concern that experimental drug might not be the best option. Poor accrual and extended enrollment timelines are common factors in causing trials, particularly cancer trials, to close, wasting time, money, and limited patient resources (Source: Oncology Nurse Advisor).

CSSi works tirelessly each and every day to overcome this predetermined statistic and the barriers associated with it. We've successfully completed global oncology programs in adult and pediatric populations, including, but not limited to:

•   Bladder Cancer
•   Breast Cancer
•   Cancer Pain
•   Colorectal Cancer
•   Gastrointestinal Cancer
•   Glioblastoma
•   Head & Neck Cancer
•   Leukemia

•   Melanoma
•   Multiple Myeloma
•   Non-Hodgkin's Lymphoma
•   Non-Small Cell Lung Cancer
•   Ovarian Cancer
•   Pancreatic Cancer
•   Prostate Cancer
•   Renal/Kidney Cancer


In addition to developing and executing effective site-based enrollment plans, CSSi has identified potential sources of referrals for investigators at tumor board meetings, placed study information into oncology programs at world-leading oncology conferences, placed study-specific advertisements in well-renowned oncology journals to garner interest from new and referring physicians, and organized "meet and greets" and "coffee meetings" prior to grand rounds in hospital oncology departments near investigators' offices.

Our newest solution, MyClinicalTrial ID, accesses de-identified data from site EMRs to pulse sites as part of feasibility as well as patient recruitment to validate and/or enroll studies. This can be done very efficiently for oncology programs, where patients need to be captured at a set point in their treatment. Pulsing the EMR repeatedly can yield patients that may have otherwise been missed or overlooked.

CSSi's extensive experience in oncology patient recruitment has proven to reduce enrollment timelines and meet budgets for guaranteed trial success. With the right trial design, site selection, and enrollment strategy, your recruitment targets can easily be met in a cost-effective and timely manner.


Are you tough enough to wear pink?

October is Breast Cancer Awareness Month. CSSi understands the importance of bringing awareness to breast cancer and other cancers through clinical trial awareness and education as well as workplace activities.

This year, CSSi encouraged its employees to wear their best pink attire for "Wear Pink" Wednesdays, to help raise awareness and show its support for the 1 in 8 women who struggle with breast cancer. We also donated to the National Breast Cancer Foundation. CSSi was the cause of a significant donation towards a cure for breast cancer.

CSSi Breast Cancer Awarness Day 2017
 

MCT ID: The Innovative Solution to Study Success

December 1, 2017

MCT ID logo

 

MyClinicalTrial (MCT) ID is a query tool that positively impacts a study's feasibility, site selection and patient recruitment processes, by reducing timelines and decreasing costs. MCT ID utilizes de-identified patient data and is conducted through a confidential and HIPAA compliant process. MCT ID can set up your study for success and meet your enrollment goals in two ways:

MCT Site ID for Feasibility

MCT Site ID reduces the risks and guesswork associated with the investigator identification process. MCT Site ID allows sponsors/CROs to assess a site's access to protocol-eligible patients by comparing a protocol's I/E criteria versus a site's patient database.

MCT Patient ID for Recruitment

MCT Patient ID increases a site's enrollment rate by querying real-time medical data versus a protocol's I/E criteria, yielding patients that are ready to be screened for a study. When paired with our Local Enrollment Specialist solution, MCT Patient ID decreases the time it takes for busy sites to identify and recruit eligible patients.

MCT ID is the key to avoiding study start-up and enrollment delays, and is the solution to efficient, lower cost clinical trial execution.

Reduce Cost - Decrease Time - Identify Patients

Transforming how sites are selected, patients are recruited and trials are enrolled


Let us help you achieve enrollment success. Talk to us today about how MCT ID can help your current or next clinical trial.


 

Happy Holidays from CSSi!

December 12, 2017

At this joyous time of year, CSSi is grateful for its work with you. We wish you abundance, happiness, and peace in a new year filled with hope. Happy holidays!

CONNECT WITH US

 

How to be Proactive with Your Recruitment Planning in 2018

December 27, 2017

Do You Have a Plan for Recruitment SUCCESS in the New Year? Failing to plan is planning to fail.

According to a recent report from the Tufts Center for the Study of Drug Development, most studies fail to meet enrollment requirements for a variety of reasons. Study delays are a direct result of unmet enrollment goals, which causes study timelines to double, or even triple, from what was originally planned for. The study budget can also become compromised when recruitment challenges arise, as costs begin to increase.

chart of planning success

Why Does This Happen?

The issue is that not enough time is spent developing the right strategies and tools for the sites to use in their enrollment plans. Sites typically lack the knowledge, ability, and most importantly, the time to effectively implement a successful enrollment plan. Other factors causing enrollment goals not to be met are:

  • The inability to select the right sites with eligible patients for your study
  • The lack of site-specific enrollment planning
  • Sites not being provided with effective or no recruitment tools (brochures, flyers, advertisements)
  • Protocols becoming more difficult
  • Ineffective recruitment materials
  • Competitive studies at the site
  • Sites losing interest in the difficult-to-enroll studies
  • Patients not being well-informed about clinical trial participation
  • Too much time spent on developing a recruitment (and retention) plan
Watch being placed into a piggy bank.

Here are a few questions you should ask yourself when conducting a study:

  1.   Do you provide sites with the appropriate educational and awareness tools?
  2.   Are you identifying the best place to find patients and the necessary recruitment tools to convert interest into enrollment?
  3.   Are you getting enrollment plans from your sites showing how they will hit their enrollment goals?

Patient accrual in clinical trials relies heavily on effective patient recruitment. The truth lies in the planning and with being proactive.

How Can CSSi Help?

CSSi has developed a "proven process" that identifies, educates and recruits eligible patients for studies. Through this process, we are able to provide sites with enrollment plans that fit their specific needs and the right tools and customized services needed to maximize their enrollment goals. Our tools and service offerings are customizable to each study:

Local Enrollment Specialists
Validating Sites' Patient Databases
Digital Media
Traditional Media
Creative Development
Community Awareness
Project Management & Reporting
Patient Retention

We ensure the most efficient and cost-effective method to reaching enrollment goals - on time, every time.


CSSi will provide you with a complimentary enrollment plan and recommended tools to set your study up for successful enrollment.

CLICK the "Yes, I'm interested!"

Yes, I am interested.

No, I am not interested.

CONNECT WITH US

 

CSSi Celebrates Glaucoma Awareness Month

January 31, 2018

MCT ID logo

 

picture of an eye

 

Eye Exam

January is Glaucoma Awareness Month! CSSi has PROVEN enrollment capability within global ophthalmology clinical studies. CSSi's solutions are timely, innovative and draw on extensive experience.

We've enrolled multiple studies for ophthalmic indications, including but not limited to:

  • Glaucoma/OHT
  • Cataract
  • Choroideremia
  • Conjunctivitis
  • Age-Related Macular Degeneration (Dry & Wet)
  • Uveitis
  • Diabetic Macular Edema
  • Dry Eye
  • Contact Lenses
  • Retinal Disease

The launch of screening events is a great example that can help identify five to 10 glaucoma or ocular hypertension patients per site for each event. This solution eliminates site frustration by channeling only highly eligible patients for further screening on the site.

Ophthalmology Case Study image link

Situation

CSSi was asked to support a Wet Age-Related Macular Degeneration (Wet AMD) study that was on track to finish 10 months behind the goal.

Solution

Each site had a detailed enrollment assessment completed to determine their enrollment challenges. A community awareness program was designed to target caregivers and medical professionals around each site. A localized television advertising campaign was implemented to raise awareness about the condition and the clinical trial. CSSi worked with each site to ensure the enrollment plan was being followed and that referrals were contacted within a timely manner.

Time Savings - 8 months

Results

CSSi's outreach campaign distributed 20,000+ materials to 250+ organizations near sites that targeted the 50+ population. Our advertising campaign generated 11,180 calls and referred 1,087 patients to sites for further screening. Over a three-month period, the recruitment campaign increased the enrollment rate by 151% and shaved eight months off the prior enrollment pace.

Need help enrolling your current or next ophthalmology study?

 

CSSi at SCOPE = So Much Newness & FREE Giveaways to Love

February 9, 2018

CSSi logo with hearts

 

CSSi is making its final preparations for the start of next week's

9th Annual SCOPE Summit

Come see us (at Booth #609) while we present our demo of MyClinicalTrial ID (MCT ID), a EMR-based platform that positively impacts a study's feasibility, investigator selection and patient recruitment processes by reducing timelines and decreasing costs. While there, check out our giveaways and leave your business card with us for a chance to win a Kate Spade purse (scroll down for details)!

CSSi representatives - Chris Trizna (President), Charlie Speno (Vice President), Ryan Haynes, MT (ASCP) (Director, Clinical Research), and Howard Daniels (Director, Business Development) - will be at the booth to answer your questions and address your patient recruitment needs.

We look forward to seeing you there!

If you don't already know, CSSi is a global, full-service patient recruitment and retention firm offering:

Site Feasibility

Fully Integrated EMR-Based Platform:

  • Validates Site EMR Data
  • HIPAA Compliant
  • Customizable
  • Confidential
  • Rapid Results -
    1. IDs Sites & Patients
    2. Reduces Timelines
    3. Decreases Costs
Patient Recruitment

Enhanced Site Engagement

Strategic Enrollment Planning

Experienced Local Enrollment Specialists

Top-Notch In-House Services:

  • Traditional & Digital Media
  • Creative Development
  • Project Management & Reporting
Patient Retention

90-95% Retention Rates

Maximized Patient Engagement

Automated Appointment Reminder System

Efficient Study Compliance Solutions

Did You Know?

To Date, CSSi Has:
Recruited for 2,000+ Studies
Supported 40+ Countries
Generated 1,000,000+ Calls of Interest
Supported 4,000+ Sites
Screened 800,000+ Patients
 

More about our KATE SPADE Giveaway:

Valintine's Day Giveaway!
Enter to win in two easy steps:
  1. 1.   Stop by the CSSi booth (#609).
  2. 2.   Leave your business card with us, or fill out a contact card.

**One winner will be chosen. The random draw will be on February 14 (Valentine's Day)!**

Want more chances to win? Any of the following will get your name entered into the drawing:
  1. 1.   Follow CSSi on LinkedIn.
  2. 2.   Like the CSSi Facebook Page.
  3. 3.   Follow us on Twitter & Tweet: "I LOVE CSSi! #SCOPE2018".
 

CSSi Continues to Help Advance Rare Disease Clinical Research

February 28, 2018

February 28 Rare Disease Day world wide color bar

 

Rare Disease Day 2018

Today is Rare Disease Day. The day represents a global effort to raise awareness amongst the general public and decision-makers about rare diseases and their impact on patients' lives.

It is estimated that 350 million people worldwide suffer from approximately 7,000 different types of rare diseases and disorders.¹

This year's theme is research. Clinical trials for rare diseases can have a huge impact on this particular patient community by expanding limited treatment options and expediting the arrival of new therapies to market.

Rare Disease Day hand holding ribbon
A Unique Approach to Rare Disease Clinical Research

CSSi recognizes that rare disease studies are complex and amongst the most challenging to enroll and retain patients. This is due to the lack of time, resources and knowledge needed to effectively identify and recruit these difficult-to-find patients. Without the appropriate tools, resources and education to identify eligible patients, no interest is generated, thus slowing enrollment and causing higher drop-out rates.

For recruitment, technology and clinical challenges, CSSi has developed the following solutions:

We take a special approach to overcoming the enrollment and retention barriers associated with rare disease clinical trials. We listen to and understand the needs and perspectives of all stakeholders involved with the study and incorporate their voices into the overall recruitment planning process. It's these voices that are the driving force behind clinical research solutions.

color bar

Our Rare Disease Experience

CSSi has successfully enrolled and retained patients in many rare disease clinical trials, including:

Amyloidosis
Alzheimer's Disease
Anemia, Hemolytic, Acquired Autoimmune
Cystic Fibrosis
Familial Hypercholesterolemia
Familial Hypophosphatemia
Gastroparesis
Glioblastoma Multiforme
Graves' Disease
Hemophilia A
Huntington's Disease
Idiopathic Pulmonary Fibrosis
Keratosis, Seborrheic
Leiomyosarcoma
Macular Degeneration (Dry and Wet)
Melanoma, Malignant
Ménière's Disease
Meningococcal Meningitis
Multiple Myeloma
Multiple Sclerosis
Orthostatic Hypotension
Osteonecrosis
Posterior Uveitis
Pulmonary Arterial Hypertension
Refractory Celiac Disease
Renal Cell Carcinoma
Restless Legs syndrome
Scleroderma
Sickle Cell Disease
Ulcerative Colitis
 
color bar

 

We have the experience, expertise and tools for all of your rare disease needs, from preclinical, clinical trials and post-commercialization.

 

color bar

 

 

Keep Your Eyes Sharp During Eye Wellness Month!

March 19, 2018

Girl with glasses working on a tablet.

March is Save Your Vision Month and Workplace Eye Health & Safety Month

Eyesight is a gift; it should be cherished and never taken for granted. Every March, we're reminded about the importance of eye health and vision care. This awareness month focuses on the dangers of blue light and the impact of digital devices on vision as well as encourages eye injury prevention to promote eye health at work.

chart of planning success

spend more than two hours each day using a digital device¹

March is also an ideal time to make a comprehensive eye exam appointment with a doctor of optometry and renew your commitment to healthily vision.

Eye Injuries at Work

The workplace can be a dangerous place for your eyes. According to the American Association of Ophthalmology (AAO), more than 20,000 eye injuries at work occur each year. Your eyesight can be at risk due to over exposure to digital screens, a small particle abrasion in the eye, chemical or solvent splashing, flying debris or using tools. The AAO claims that 90% of all work-related eye injuries are preventable, however.²

Could you recognize an eye injury if you had one? Some signs to keep an "eye" out for are:

  • Computer Visions Syndrome (CVS)/Digital Eye Strain
  • Pain in the eye
  • Blurred vision
  • Eye irritation (burning or stinging)
  • Trouble moving one eye
  • Blood in the eye
  • Dry eyes
  • Irregular pupil size
  • Sleep problems/fatigue
  • Headaches
  • Neck and shoulder pain
  • Back strain

It's extremely important to be aware of and practice eye safety. The consequences of not doing so could potentially lead to loss of vision.

Protecting Your Eyes

Your eyes are both precious and complex, so don't wait around for the burning, itching, stinging or straining to set in. Consider the below tips for keeping your eyes healthy:

  1.   Schedule a biennial eye exam. Regular check-ups can help enhance and preserve your vision, thus, increasing work productivity and reducing work-related accidents as well as keeping your eyes feeling comfortable.
  2.   Take a break from computer, phone and TV screens.
  3.   Eat vision-enhancing foods.
  4.   Drink water regularly.
  5.   Wear eye protection (i.e. sunglasses, safety glasses, safety goggles and face masks).
  6.   Stop or avoid smoking.
  7.   Practice the 20-20-20 rule. For 20 minutes, look at something that's 20 feet away for 20 seconds intervals.
  8.   Use artificial tears.
  9.   Remember to blink.

Eye care and safety actions are easy to incorporate and invaluable to maintain a lifetime of healthy vision.

Clinical Trials in Vision Research

Clinical trials in vision research are conducted to discover safe and effective methods for preventing, diagnosing and treating eye disease and vision loss. Over the years, research studies have led to new medications, surgeries and methods for disease detection that have saved or improved the eyesight of millions of people.³

Are you currently conducting or thinking about conducting a clinical trial related to an eye condition or disease? If so:

CSSi has enrolled multiple studies for ophthalmic indications, including:

  • Uveitis
  • Diabetic Macular Edema
  • Dry Eye
  • Contact Lenses
  • Retinal Disease

Sources:
¹https://www.eyecarespecialties.com/2018/03/07/march-is-workplace-eye-wellness-month/
²https://www.aao.org
³https://nei.nih.gov/health/clinicaltrials_facts

Respiratory Clinical Trial Expertise

March 27, 2018

Girl blowing her nose in a field of flowers

Respiratory Clinical Trial Expertise

Recruitment of patients into respiratory trials remains challenging, time-consuming and very costly. CSSi understands the unique challenges of respiratory clinical research and is proactive in finding affordable and effective solutions. We offer full-service patient recruitment and retention programs, strategic enrollment planning, best-in-class technologies and certified Local Enrollment Specialists.

CSSi has enrolled multiple studies in a variety of respiratory indications such as:

  • Allergic Rhinitis (Seasonal & Chronic)
  • Allergy
  • Asthma
  • Bronchitis
  • Common Cold and Cough
  • COPD
  • Cystic Fibrosis
  • Dust Mite Allergies
  • Emphysema
  • Idiopathic Pulmonary Fibrosis
  • Influenza
  • Lung Cancer
  • Nasal Allergy
  • Pediatric Allergic Rhinitis (Hay Fever)
  • Pediatric Asthma
  • Pharyngitis
  • Pneumonia
  • Pulmonary Arterial Hypertension
  • Respiratory Syncytial Virus (RSV) Infection
  • Rhinoconjunctivitis
  • Sinusitis
  • Sleep Apnea
  • Smoking Cessation

CSSi has the experience, commitment and resources to assist with any global recruitment or retention programs. We tailor our highly-effective, individualized recruitment plans to each protocol and site with the mind set of meeting your enrollment goals within a reasonable amount of time and in a cost-effective manner.

Dad and boy playing soccer in the grass

What can CSSi do for you and your study, you ask? Contact us today to find out!

Endometriosis Awareness Month

March 29, 2018

Endometriosis Awareness Month

March may be coming to an end, but this does not mean that encouraging and empowering women with this disorder to make informed decisions about their treatment options has to. Clinical research is crucial to the advances in scientific understanding of women's unique health needs and conditions. CSSi is committed to helping improve endometriosis treatment through research and educating patients about women's health clinical trials.

CSSi has completed a wide variety of women's health programs, including:

  • Bacterial Vaginosis
  • Bone Density
  • Breast Cancer
  • Chlamydia
  • Contraception
  • Endometriosis
  • Hormone Replacement
  • Hot Flashes/Vasomotor Symptoms
  • Iron Deficiency
  • Nocturia
  • Overactive Bladder (OAB)
  • Ovulation
  • Uterine Fibroids
  • Vaginal Atrophy
Woman drinking a cup of coffee and looking through emails.

Recruiting and engaging patients for women's health studies has taught CSSi that:

  1.   Study education and awareness are important facets of the recruitment strategy for these studies.
  2.   Advertising is an effective way of reaching a large number of patients quickly and providing the necessary study information. The referrals generated as a result of this recruitment effort keep sites engaged.
  3.   Once sites have exhausted their private practice database, they can quickly get frustrated with low enrollment. CSSi's support services engage the sites and keep them committed to the enrollment plan.

Your Study's Enrollment Success Starts Here!

Why is CNS Patient Recruitment So Difficult?

April 19, 2018

CSSi Answers:
Why is CNS Patient Recruitment So Difficult?

Clinical trials in CNS indications are notoriously difficult to recruit (and retain) patients for. Why? CNS diseases and conditions are so wide-ranging in their types, symptoms and outcomes that the breadth of research can be extensive and overwhelming. For doctors and researchers, trying to unravel the complexity of the human brain and its functions is not an easy task. Equally problematic is the millions of people across the globe affected by CNS diseases.

But why are CNS indications more complicated to recruit for than other indications? Here's a look at a few of the major patient recruitment challenges for CNS studies:

Woman juggling image of challenges.

 

CSSi has successfully executed over 200 CNS/psychiatric programs, including Bipolar Depression, Major Depressive Disorder, Treatment-Resistant Depression, Depression, Anxiety, Schizophrenia, ADHD, Generalized Anxiety Disorder and other CNS indications.

Chart of CNS Experiance.

 

How do we achieve CNS study success? Two words - education and awareness. Because CNS patients are often so ill, CSSi targets our outreach messages to their caregivers. We believe it is imperative to develop close ties and partnerships with CNS advocacy and support groups because CNS families regularly turn to these groups for information on clinical trials and important new advances being made for the treatment of CNS disorders. At CSSi, we believe that even though there are challenges recruiting CNS patients, the benefits are worth it!

Questions about our CNS expertise and services?

Need Help Enrolling Your Current or Next GI Study?

April 26, 2018

CSSi Answers:
Why is CNS Patient Recruitment So Difficult?

Row of grade school children from diverse backgrounds.

 

Over the past 13 years, CSSi has completed over 100 Gastroenterology (GI) patient recruitment programs and developed extensive global expertise in the following GI therapeutic areas:

  • Anal Fissures
  • Bowel Dysfunction
  • Bowel Preparation
  • Celiac Disease
  • Clostridium difficile
  • Colon Cancer (Screening, Treatment)
  • Constipation (Chronic, Idiopathic)
  • Crohn's Disease
  • Diverticulitis
  • Gallstones
  • Gastroesophageal Reflux Disease
  • Gastroparesis
  • Heartburn
  • Hemorrhoids
  • Hepatitis
  • HIV-Associated Diarrhea
  • Irritable Bowel Syndrome
  • Nonalcoholic Steatohepatitis
  • Opioid-Induced Constipation
  • Peptic Ulcer (Stomach, Duodenum)
  • Ulcerative Colitis
  • Ulcerative Proctitis

 

Click Here to read about a recent pediatric IBS-C study, supported by CSSi. Enrollment success for this challenging study was achieved by our Local Enrollment Specialists (LESs), their quick thinking and the support services they provided to the sites. Within a matter of weeks, our LES team made site introductions, developed and rolled out an all-encompassing enrollment plan and conducted a comprehensive chart review from hundreds of potential patients. The LES supported sites screened 16 times more patients than the sites that did not utilize the LES services. Our LESs are equipped with the knowledge, experience and tools for efficient patient identification, screening and enrollment.

Your study deserves support that exceeds expectations!

Three Common Misconceptions About CSSi

May 31, 2018

Having been in the clinical research industry for over 13 years, we tend to assume people know exactly what we do here at CSSi. Unfortunately, because this is an ever-evolving industry, misconceptions arise and can cause confusion about exactly who we are and what we do. So, we would like to dispel what we consider the most common misconceptions:

But why are CNS indications more complicated to recruit for than other indications? Here's a look at a few of the major patient recruitment challenges for CNS studies:

Misconceptions vs Reality ribbon image

 

CSSi is an advertising agnecy image

CSSi has an experienced digital and traditional media team; however, that is not all we have to offer! CSSi is a full-service global patient recruitment firm, offering a variety of in-house services: traditional and digital advertising, graphic design, technology solutions, community awareness, and project management and reporting. But what makes CSSi unique is our team of Local Enrollment Specialists (LESs), who work directly with the sites to maximize study enrollment.

CSSi works only with investigative sites, image

CSSi works with sites, yes. But, not just sites. Over the years, we have partnered with top pharmaceutical companies, CROs, and SMOs.

CSSi only supports U.S.-based clinical trials, image

CSSi has worked in over 20 therapeutic areas, developed relationships with over 1,000 sites in over 40 different countries, and successfully supported the recruitment for hundreds of studies. CSSi's global team of LESs are local to their region, speak the native language, and are familiar with the regulatory environment. Every study supported is individually evaluated for its international feasibility. Because of our widespread global presence, we have offices located in North America, Europe, and Asia.

Interested in learning more about CSSi?

DIA 2018 - See you next week?

June 19, 2018

MyClinicalTrial ID

Accelerating Patient Recruitment

 

CSSi works quickly, before the popsicle melts

Take a bite out of our
HIGH-IMPACT
STUDY ENROLLMENT
SUPPORT

Time is
melting
away!

Ask us how we can
help get your study
back on track!
 

Join us at #DIA2018 from June 25-27! Stop by our Booth #2305 and submit your business card for three chances to win a Kate Spade tote.

If you're interested in scheduling a one-on-one meeting with a CSSi representative during DIA, go to www.cssienroll.com/event.html.

We look forward to seeing you in Boston!

 
Offices and Locations
  • North America
  • 6958 Aviation Blvd
  • Suite H
  • Glen Burnie, MD 21061
  • P: 866.277.4888
  • E-mail: info@cssienroll.com
  • Europe
  • Kemp House,
  • City Road,
  • London, EC1V 2NX
  • P: 0203 693 3829
  • Asia
  • G-A, “Hyndava Techno Park”,
  • Plot No. 12,
  • Survey No. 64,
  • Hitec City, Phase 2,
  • Madhapur,
  • Hyderabad - 500081